Rituximab biosimilar - Sandoz

Drug Profile

Rituximab biosimilar - Sandoz

Alternative Names: GP 2013; Rixathon; Riximyo

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sandoz
  • Developer Sandoz; University of Leeds
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Microscopic polyangiitis; Rheumatoid arthritis; Wegener's granulomatosis
  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 12 Sep 2017 Preregistration for Rheumatoid arthritis, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and Follicular lymphoma in USA (IV)
  • 08 Sep 2017 Efficacy data from the phase III ASSIST-FL trial in Follicular lymphoma presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 19 Jun 2017 Registered for Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Follicular lymphoma, Microscopic polyangiitis and Wegener's granulomatosis and Rheumatoid arthritis in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top